flumatinib + imatinib

Phase 2UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myelogenous Leukemia, Chronic

Conditions

Myelogenous Leukemia, Chronic

Trial Timeline

Aug 1, 2011 → Dec 1, 2014

NCT ID

NCT01503502

About flumatinib + imatinib

flumatinib + imatinib is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Myelogenous Leukemia, Chronic. The current trial status is unknown. This product is registered under clinical trial identifier NCT01503502. Target conditions include Myelogenous Leukemia, Chronic.

What happened to similar drugs?

8 of 20 similar drugs in Myelogenous Leukemia, Chronic were approved

Approved (8) Terminated (1) Active (11)

✅micafungin + posaconazoleAstellas PharmaApproved

✅NilotinibNovartisApproved

✅imatinib mesylateNovartisApproved

✅NilotinibNovartisApproved

🔄NilotinibNovartisPhase 3

🔄nilotinib + imatinibNovartisPhase 3

🔄imatinib mesilate + interferon-alpha (INF-a) + cytarabine (ARA-C)NovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01503502	Phase 2	UNKNOWN	Aug 1, 2011	Dec 1, 2014	Myelogenous Leukemia, Chronic

Competing Products

20 competing products in Myelogenous Leukemia, Chronic

See all competitors

Product	Company	Stage	Hype Score
Bisantrene	Race Oncology	Phase 2	29
Bisantrene + Fludarabine + Clofarabine	Race Oncology	Phase 2	25
Milademetan + AZA + Milademetan	Daiichi Sankyo	Phase 1	21
micafungin + posaconazole	Astellas Pharma	Approved	43
decitabine Induction Chemotherapy + Induction Chemotherapy	Eisai	Phase 2	27
decitabine (5-aza-2'deoxycytidine)	Eisai	Phase 2	35
Decitabine	Eisai	Phase 2	35
Decitabine + Gemtuzumab ozogamicin	Eisai	Phase 2	35
Ondansetron + Palonosetron	Eisai	Phase 2	35
decitabine (5-aza-2'deoxycytidine)	Eisai	Phase 2	35
Decitabine + Decitabine	Eisai	Phase 2	27
Decitabine	Eisai	Phase 2/3	38
KW-2449	Kyowa Kirin	Phase 1	21
KW-2449	Kyowa Kirin	Phase 1	21
ABT-199	AbbVie	Phase 2	35
Posaconazole + ABT-199 + Decitabine + Azacitidine	AbbVie	Phase 1	21
Venetoclax + Cytarabine	AbbVie	Phase 1/2	32
AZD4877	AstraZeneca	Phase 1	21
MK-8776 + Cytarabine	Merck	Phase 1	21
MK0457	Merck	Phase 1	29